普拉克索和舍曲林能治疗抑郁症吗？

Pramipexole can treat depression. Pramipexole is an anti-Parkinson's disease drug that also treats depression in patients with Parkinson's disease. Sertraline can be used to treat symptoms related to depression.

Although it is mainly used to treat Parkinson's disease, it is clearly stated in the "China Parkinson's Disease Treatment Guidelines (Fourth Edition)" that pramipexole can be used to treat depressive symptoms in patients with Parkinson's disease.

Clinical studies have shown that pramipexole has good antidepressant effects. The antidepressant pharmacological effects are mainly related to the binding effect of dopamine D3 receptors, which can significantly improve the functional response of the patient's body, thereby alleviating the symptoms of depression.

Pramipexole Indications

Pramipexole is a new dopamine receptor agonist that binds with high selectivity and specificity to the D2 subfamily of dopamine receptors, has preferential affinity for the D3 receptor, and has complete intrinsic activity.

Pramipexole alleviates Parkinson's disease by stimulating dopamine receptors in the striatum. Animal experiments show that pramipexole has the effect of inhibiting the synthesis, release and renewal of dopamine and is used to treat the signs and symptoms of adult idiopathic Parkinson's disease.

The effect of pramipexole in treating depression

In 2 randomized controlled trials, 1 open-label trial, 2 naturalistic studies, and 2 retrospective studies, the first RCT showed a significantly higher response of 67% to pramipexole compared with placebo, which was only 20%.

The second RCT showed that pramipexole resulted in higher response and remission outcomes compared with placebo, at 60% and 40% respectively. Pramipexole was generally well tolerated. Various studies have shown some promise in using pramipexole in the treatment of treatment-resistant bipolar depression.

Across 5 randomized controlled trials, 3 open-label trials, and 5 observational studies with a total of 504 participants, the overall short-term response rate was 52.2% and the response rate was 36.1%, and the overall long-term response rate was 62.1% and the response rate was 39.6%.

In randomized controlled trials, patients treated with pramipexole had higher response rates compared with placebo and were acceptably and well-tolerated.

pramipexole

1. Mental illness: Common symptoms include abnormal dreams, impulse control disorders and obsessive-compulsive behaviors, confusion, hallucinations, and insomnia. Occasionally, binge eating, compulsive shopping, delusions, overeating, hypersexuality, sexual desire disorder, paranoia, pathological gambling, agitation, delirium, and rarely mania.

2. Nervous system diseases: Very common ones include dizziness, dyskinesia, and drowsiness. Common ones include headache. Occasionally, forgetfulness, convulsions, sleep attacks, and syncope are common.

3. Eye diseases: Common ones include visual impairment, such as double vision, blurred vision, and vision loss.

4. Gastrointestinal diseases: Nausea is very common, and constipation and vomiting are common.

5. Skin and subcutaneous tissue diseases: occasional allergies, itching, and rashes.

6. Systemic symptoms and administration site conditions: Common symptoms include fatigue, peripheral edema, weight loss, decreased appetite, and occasionally weight gain.

References:

1. Dionys V, Sienaert P. Pramipexol in bipolar depression: a literature review and clinical recommendations. Tijdschr Psychiatr. 2021;63(9):658-664. Dutch. PMID: 34647304.

2. Tundo A, de Filippis R, De Crescenzo F. Pramipexole in the treatment of unipolar and bipolar depression. A systematic review and meta-analysis. Acta Psychiatr Scand. 2019 Aug;140(2):116-125. doi: 10.1111/acps.13055. Epub 2019 Jun 9. PMID: 31111467.

Recommended related articles: